Avadel Pharmaceuticals PLC (id:6508 AVDL)
10.14 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/24/2024 7:41:41 AM)
Exchange closed, opens in 1 hour 48 minutes
-1.55 USD (-1.55%)
-5.23 USD (-5.23%)
-12.36 USD (-12.36%)
-27.10 USD (-27.10%)
-27.31 USD (-27.31%)
39.29 USD (39.29%)
-41.29 USD (-41.29%)
-45.95 USD (-45.95%)
About Avadel Pharmaceuticals PLC
Market Capitalization 994.45M
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
| Headquarters (address) |
10 Earlsfort Terrace Dublin 2 Ireland |
| Phone | 353 1 901 5201 |
| Website | https://www.avadel.com |
| Employees | 154 |
| Sector | Healthcare |
| Industry | Drug Manufacturers Specialty & Generic |
| Ticker | AVDL |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 9.41 - 19.09 |
| Market Capitalization | 994.45M |
| P/E trailing | -5.16 |
| P/E forward | 15.18 |
| Price/Sale | 7.20 |
| Price/Book | 13.32 |
| EPS | 3.00 |
| EPS Ireland (ID:161, base:52) | 2.88 |